IRIS Accounts Production v26.1.0.640 09789742 director 1.10.24 30.9.25 30.9.25 false true false false true false iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 09789742 2024-09-30 09789742 2025-09-30 09789742 2024-10-01 2025-09-30 09789742 2023-09-30 09789742 2023-10-01 2024-09-30 09789742 2024-09-30 09789742 ns15:EnglandWales 2024-10-01 2025-09-30 09789742 ns14:PoundSterling 2024-10-01 2025-09-30 09789742 ns10:Director1 2024-10-01 2025-09-30 09789742 ns10:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 09789742 ns10:SmallEntities 2024-10-01 2025-09-30 09789742 ns10:AuditExempt-NoAccountantsReport 2024-10-01 2025-09-30 09789742 ns10:SmallCompaniesRegimeForDirectorsReport 2024-10-01 2025-09-30 09789742 ns10:SmallCompaniesRegimeForAccounts 2024-10-01 2025-09-30 09789742 ns10:FullAccounts 2024-10-01 2025-09-30 09789742 ns10:RegisteredOffice 2024-10-01 2025-09-30 09789742 ns5:CurrentFinancialInstruments 2025-09-30 09789742 ns5:CurrentFinancialInstruments 2024-09-30 09789742 ns5:ShareCapital 2025-09-30 09789742 ns5:ShareCapital 2024-09-30 09789742 ns5:SharePremium 2025-09-30 09789742 ns5:SharePremium 2024-09-30 09789742 ns5:RetainedEarningsAccumulatedLosses 2025-09-30 09789742 ns5:RetainedEarningsAccumulatedLosses 2024-09-30 09789742 ns5:PlantMachinery 2024-10-01 2025-09-30 09789742 ns5:PlantMachinery 2024-09-30 09789742 ns5:PlantMachinery 2025-09-30 09789742 ns5:PlantMachinery 2024-09-30 09789742 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-09-30 09789742 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-09-30 09789742 ns5:CurrentFinancialInstruments 2024-10-01 2025-09-30

REGISTERED NUMBER: 09789742 (England and Wales)

Unaudited Financial Statements for the Year Ended 30 September 2025

for

Camnord Pharma Limited

Camnord Pharma Limited (Registered number: 09789742)

Contents of the Financial Statements

for the Year Ended 30 September 2025

Page |

Company Information | 1 |

Balance Sheet | 2 |

Notes to the Financial Statements | 4 |

Camnord Pharma Limited

Company Information

for the Year Ended 30 September 2025

| DIRECTOR: | Dr A Kumar

| REGISTERED OFFICE: | 23 Portugal Place

| Cambridge

| Cambridgeshire

| CB5 8AF

| REGISTERED NUMBER: | 09789742 (England and Wales)

Camnord Pharma Limited (Registered number: 09789742)

Balance Sheet

30 September 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Tangible assets | 5 | - |  | 64,496 |  |

CURRENT ASSETS

Debtors | 6 | 156,692 |  | 160,402 |  |

Cash at bank | 367,283 |  | 369,487 |  |

523,975 |  | 529,889 |  |

CREDITORS

Amounts falling due within one year | 7 | 2,943,723 |  | 2,891,468 |  |

NET CURRENT LIABILITIES | (2,419,748 | ) | (2,361,579 | ) |

TOTAL ASSETS LESS CURRENT LIABILITIES | (2,419,748 | ) | (2,297,083 | ) |

PROVISIONS FOR LIABILITIES | - |  | 12,254 |  |

NET LIABILITIES | (2,419,748 | ) | (2,309,337 | ) |

CAPITAL AND RESERVES

Called up share capital | 123 |  | 123 |  |

Share premium | 3,184,404 |  | 3,184,404 |  |

Retained earnings | (5,604,275 | ) | (5,493,864 | ) |

SHAREHOLDERS' FUNDS | (2,419,748 | ) | (2,309,337 | ) |

Camnord Pharma Limited (Registered number: 09789742)

Balance Sheet - continued

30 September 2025

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 September 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 September 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 29 March 2026 and were signed by:

Dr A Kumar - Director

Camnord Pharma Limited (Registered number: 09789742)

Notes to the Financial Statements

for the Year Ended 30 September 2025

1. | STATUTORY INFORMATION

| Camnord Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

| The presentation currency of the financial statements is the Pound Sterling (£).

2. | STATEMENT OF COMPLIANCE

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006.

3. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| The financial statements have been prepared under the historical cost convention.

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.

| Plant and machinery etc | - | 10% on cost

| Financial instruments

| A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instruments.

| Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes, in effect, a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

| Debt instruments are subsequently measured at amortised cost.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Camnord Pharma Limited (Registered number: 09789742)

Notes to the Financial Statements - continued

for the Year Ended 30 September 2025

3. | ACCOUNTING POLICIES - continued

| Research and development

| Expenditure on research and development is written off in the year in which it is incurred.

| Foreign currencies

| Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

| Going concern

| The Company incurred a loss for the year and as at the year end has, as disclosed on the balance sheet, net liabilities. The financial statements are prepared on the going concern basis on the assumption that the Company will continue to receive sufficient financial support from its shareholders to provide sufficient funds to enable it to meet its liabilities as they fall due.

4. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 1 (2024 - 1 ) .

5. | TANGIBLE FIXED ASSETS

| Plant and

| machinery

| etc

£ |

| COST

| At 1 October 2024 | 71,662 |  |

| Disposals | (71,662 | ) |

| At 30 September 2025 | - |  |

| DEPRECIATION

| At 1 October 2024 | 7,166 |  |

| Eliminated on disposal | (7,166 | ) |

| At 30 September 2025 | - |  |

| NET BOOK VALUE

| At 30 September 2025 | - |  |

| At 30 September 2024 | 64,496 |  |

6. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Amounts owed by group undertakings | 2 |  | - |  |

| Other debtors | 156,690 |  | 160,402 |  |

156,692 |  | 160,402 |  |

| Included within other debtors disclosed above is a balance of £51 (2024 - £51) in relation to deposits, a balance of £115,847 (2024 - £150,371) in relation to tax refunds and a balance of £40,792 (2024 - £9,980) in relation to VAT.

Camnord Pharma Limited (Registered number: 09789742)

Notes to the Financial Statements - continued

for the Year Ended 30 September 2025

7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade creditors | 50,001 |  | 7,734 |  |

| Taxation and social security | 8,383 |  | 8,219 |  |

| Other creditors | 2,885,339 |  | 2,875,515 |  |

2,943,723 |  | 2,891,468 |  |

| Included within other creditors disclosed above is a balance of £21,165 (2024 - £21,165) in relation to accruals, a balance of £35,042 (2024 - £25,218) in relation to the Director's Loan Account and a balance of £2,829,132 (2024 - £2,829,132) in relation to a loan from shareholders.